Page last updated: 2024-09-02

s 9788 and Bradyarrhythmia

s 9788 has been researched along with Bradyarrhythmia in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ardiet, C; Barbet, N; Bastian, G; Catimel, G; Clavel, M; Dumortier, A; Evene, E; Foy, M; Froudarakis, M; Grossin, F; Guastalla, JP; Lucas, C; Mazier, B; Négrier, S; Rebattu, P; Sarkany, M; Tranchand, B	1

Trials

1 trial(s) available for s 9788 and Bradyarrhythmia

Article	Year
Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors. Cancer chemotherapy and pharmacology, 1998, Volume: 41, Issue:4 Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Bradycardia; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoplasms; Piperidines; Triazines	1998

Article

Year

Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.

Cancer chemotherapy and pharmacology, 1998, Volume: 41, Issue:4

Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Bradycardia; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoplasms; Piperidines; Triazines

1998